Proteoglycan inhibition of calcium phosphate precipitation in liposomal suspensions.
The major proteoglycan in cartilage (aggrecan) is a complex macromolecule with numerous chondroitin sulphate, keratan sulphate, and oligosaccharide substituents. It has been proposed that this macromolecule has an important role in regulating mineralization in this tissue, a process which is initiated by the deposition of apatite in matrix vesicles. We have used a liposome-centred endogenous precipitation method as a model for matrix vesicle mineralization to study the effect of the rat chondrosarcoma aggrecan and its chondroitin sulphate and core protein components on apatite formation from solution. Precipitation was initiated by encapsulating buffered (pH 7.4) 50 mmol/l KH2PO4 solutions in the aqueous centres of 7:2:1 phosphatidylcholine:dicetylphosphate:cholesterol liposomes, adding 2.25-2.65 mmol/l Ca2+ and 1.5 mmol/l total inorganic phosphate (PO4) to the suspending medium (pH 7.4, 22 degrees C), then making the intervening lipid membranes permeable to the Ca2+ ions with the calcium ionophore X-537A. Aggrecan (0.5%) in the suspending medium had no effect on intraliposomal precipitation, but severely reduced (approximately 70% reduction at 24 h) its subsequent spread into the medium. The chondroitin sulphate and core protein were similarly inhibitory. The degree to which aggrecan and its constituent parts inhibited precipitation correlated with their capacity to bind Ca2+ ions. These findings suggest that functional groups in aggrecan blocked apatite growth by linking via Ca2+ bridges to growth sites on the crystal surfaces. Similar Ca-mediated interactions may well have a critical regulatory role in cartilage mineralization.
Eanes
E D
ED
National Institute of Dental Research's Bone Research Associate Program, National Institute of Standards and Technology, Gaithersburg, MD 20899.
Hailer
A W
AW
Midura
R J
RJ
Hascall
V C
VC
D053674:Aggrecans; D000818:Animals; D002113:Calcification, Physiologic; D002130:Calcium Phosphates / Q000378:metabolism*; D002463:Cell Membrane Permeability; D011232:Chemical Precipitation; D002784:Cholesterol / Q000378:metabolism; D002809:Chondroitin Sulfates / Q000494:pharmacology; D002813:Chondrosarcoma / Q000737:chemistry; D016326:Extracellular Matrix Proteins; D037181:Lectins, C-Type; D008081:Liposomes / Q000378:metabolism*; D010755:Organophosphates / Q000378:metabolism; D010713:Phosphatidylcholines / Q000378:metabolism; D011509:Proteoglycans / Q000378:metabolism / Q000494:pharmacology*; D051381:Rats; D012996:Solutions; D014758:Viral Core Proteins / Q000494:pharmacology
C508321:Acan protein, rat; D053674:Aggrecans; D002130:Calcium Phosphates; D016326:Extracellular Matrix Proteins; D037181:Lectins, C-Type; D008081:Liposomes; D010755:Organophosphates; D010713:Phosphatidylcholines; D011509:Proteoglycans; D012996:Solutions; D014758:Viral Core Proteins; C485828:alpha-tricalcium phosphate; C485830:tetracalcium phosphate; C002290:dicetylphosphate; C485838:calcium phosphate, monobasic, anhydrous; D002809:Chondroitin Sulfates; D002784:Cholesterol; C020243:calcium phosphate; C485829:calcium phosphate, dibasic, anhydrous